Reply
Yohei Fujii, Yoshihito Uchida, Satoshi Mochida – 6 August 2015
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance
Hui Wang, Souhayla El Maadidi, Janett Fischer, Elena Grabski, Sabine Dickhöfer, Sascha Klimosch, Sinead M. Flannery, Angela Filomena, Olaf‐Oliver Wolz, Nicole Schneiderhan‐Marra, Markus W. Löffler, Manfred Wiese, Tica Pichulik, Beat Müllhaupt, David Semela, Jean‐François Dufour, Pierre‐Yves Bochud, Andrew G. Bowie, Ulrich Kalinke, Thomas Berg, Alexander N.R.
Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity
Alla Kachko, Sharon E. Frey, Lev Sirota, Ranjit Ray, Frances Wells, Iryna Zubkova, Pei Zhang, Marian E. Major – 6 August 2015 – Hepatitis C virus (HCV) neutralization occurring at the E2 region 412‐426 (EP‐I) could be enhanced when antibodies directed specifically to the E2 region 434‐446 (EP‐II) were removed from serum samples of persistently infected patients and vaccinated chimpanzees, a phenomenon of so‐called antibody interference. Here, we show that this type of interference can be observed in individuals after immunization with recombinant E1E2 proteins.
Reply
Leon A. Adams, Darrell H. Crawford, Tim K. St. Pierre, John K. Olynyk – 3 August 2015
The shear effort of measurement of portal hypertension
William Sanchez, Patrick S. Kamath – 3 August 2015
Repurposing an old drug: A low‐cost allergy medication provides new hope for hepatitis C patients
Zhilei Chen, Charles M. Rice – 3 August 2015
Does the death knell toll for phlebotomy in NAFLD?
John D. Ryan, Thomas Marjot, Jeremy F. Cobbold – 3 August 2015
Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States
Robert G. Gish, Chari A. Cohen, Joan M. Block, Carol L. Brosgart, Timothy M. Block, Ryan Clary, Loc T. Le, Michael H. Ninburg, Lorren Sandt, Kris V. Kowdley – 3 August 2015
Present and future therapies of hepatitis B: From discovery to cure
T. Jake Liang, Timothy M. Block, Brian J. McMahon, Marc G. Ghany, Stephan Urban, Ju‐Tao Guo, Stephen Locarnini, Fabien Zoulim, Kyong‐Mi Chang, Anna S. Lok – 3 August 2015 – Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million people worldwide. While treatment for HBV has improved, HBV patients often require lifelong therapies and cure is still a challenging goal.
HCV vertical transmission in pregnancy: New horizons in the era of DAAs
Tomi T. Kanninen, Douglas Dieterich, Stefania Asciutti – 3 August 2015